Sanofi joins the alpha-synuclein bandwagon, handing Korean biotech $75M for preclinical bispecific
Alpha-synuclein is gaining clout in the growing effort to crush Parkinson’s disease at its roots.
Sanofi became the latest to join the gang late Tuesday, turning to Korea’s ABL Bio to license a preclinical bispecific antibody targeting both alpha-synuclein and IGF1R — a design that it believes can lead to better penetration of the blood-brain barrier.
The French pharma giant is handing its new biotech partner $75 million in upfront cash, on top of $985 million in biobucks, $45 million of which will be near-term milestones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.